International Journal of Clinical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Current status of head and neck sarcomas in Japan in 2016 –2019: an analysis using the national cancer registry
ConclusionsHead and neck sarcomas occurred rarely, but most frequently in the nasal cavity and paranasal sinuses in Japan. Poor outcomes were observed for sarcoma patients than for non-sarcoma head and neck cancer patients. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 27, 2024 Category: Cancer & Oncology Source Type: research

Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer
ConclusionThese findings suggest that plasma THBS1 may be serving as an unfavorable prognosis predictor for HER2-enriched breast cancer and justifies the need for further research. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 27, 2024 Category: Cancer & Oncology Source Type: research

Current status of head and neck sarcomas in Japan in 2016 –2019: an analysis using the national cancer registry
ConclusionsHead and neck sarcomas occurred rarely, but most frequently in the nasal cavity and paranasal sinuses in Japan. Poor outcomes were observed for sarcoma patients than for non-sarcoma head and neck cancer patients. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 27, 2024 Category: Cancer & Oncology Source Type: research

Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer
ConclusionThese findings suggest that plasma THBS1 may be serving as an unfavorable prognosis predictor for HER2-enriched breast cancer and justifies the need for further research. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 27, 2024 Category: Cancer & Oncology Source Type: research

Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance
ConclusionPatients receiving molecular-targeted and immune therapies are at risk of experiencing profound financial toxicity and a reduced quality of life. The independently related factors that we identified have the potential to serve as indicators of profound financial toxicity and the need for specialized intervention. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 24, 2024 Category: Cancer & Oncology Source Type: research

Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study
ConclusionsCOVID-19 vaccine immunogenicity was reduced among patients with cancer, especially under several treatment regimens. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 21, 2024 Category: Cancer & Oncology Source Type: research

Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021
ConclusionThe incidence of gynecologic cancer is increasing significantly in Japan. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 21, 2024 Category: Cancer & Oncology Source Type: research

Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression
ConclusionsRFC3 was transcriptional activated by the YAP1/TEAD signaling pathway, thus promoting GC progression. RFC3 may be a promising therapeutic target for GC. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 21, 2024 Category: Cancer & Oncology Source Type: research

Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study
ConclusionsCOVID-19 vaccine immunogenicity was reduced among patients with cancer, especially under several treatment regimens. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 21, 2024 Category: Cancer & Oncology Source Type: research

Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study
ConclusionBV treatment-induced proteinuria was not associated with renal dysfunction or other adverse events. Continuing BV with caution is a possible treatment option, even after proteinuria develops, in patients with cancer and a limited prognosis. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 14, 2024 Category: Cancer & Oncology Source Type: research

Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan
ConclusionCancer cachexia was suggested to be associated with shorter TTF and a reduced number of doses in patients with pancreatic cancer who received first-line FFX or GnP treatment.Clinical Trial Registration clinicaltrials.jp: UMIN000045820. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 14, 2024 Category: Cancer & Oncology Source Type: research

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022
ConclusionLimited data are available on G-CSF prophylaxis in lung cancer. Primary prophylaxis with G-CSF may be weakly recommended in Japanese patients with NSCLC undergoing docetaxel and ramucirumab combination therapy. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 14, 2024 Category: Cancer & Oncology Source Type: research

First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data
ConclusionIO-TKI therapy exhibited superior effectiveness over IO-IO therapy in terms of PFS improvement and immediate disease progression prevention and was associated with a higher risk of treatment interruption and a lower risk of needing corticosteroids. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 12, 2024 Category: Cancer & Oncology Source Type: research

Announcement: Third Joint Committee Report on Diabetes and Cancer
(Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - February 10, 2024 Category: Cancer & Oncology Source Type: research